Last reviewed · How we verify
Deferasirox, Vitamin D and Azacitidine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Deferasirox, Vitamin D and Azacitidine (Deferasirox, Vitamin D and Azacitidine) — Groupe Francophone des Myelodysplasies.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Deferasirox, Vitamin D and Azacitidine TARGET | Deferasirox, Vitamin D and Azacitidine | Groupe Francophone des Myelodysplasies | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Deferasirox, Vitamin D and Azacitidine CI watch — RSS
- Deferasirox, Vitamin D and Azacitidine CI watch — Atom
- Deferasirox, Vitamin D and Azacitidine CI watch — JSON
- Deferasirox, Vitamin D and Azacitidine alone — RSS
Cite this brief
Drug Landscape (2026). Deferasirox, Vitamin D and Azacitidine — Competitive Intelligence Brief. https://druglandscape.com/ci/deferasirox-vitamin-d-and-azacitidine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab